Sun Sep 15 10:14:50 UTC 2024: ## Moderna Shares See Unusual Volume Decline Amidst Mixed Analyst Opinions

**Boston, MA** – Moderna, Inc. (MRNA) experienced a significant drop in trading volume on Friday, September 15th, with only 1,603,648 shares changing hands, a 62% decrease from the previous day’s volume. The stock closed at $67.79, down from the previous day’s closing price of $69.68.

The decline in volume comes amidst a mixed bag of analyst opinions on Moderna. While Goldman Sachs maintained a “buy” rating, lowering their price target to $178.00, other firms like Jefferies Financial Group and Bank of America downgraded the stock to “hold” and “neutral” respectively, adjusting their price targets downwards.

Moderna’s recent quarterly earnings report, released on August 1st, showed a beat on analysts’ earnings per share estimates but a decline in revenue compared to the previous year. The company reported a loss of $3.33 per share, surpassing expectations by $0.14, but revenue came in at $241.00 million, down 29.9% year-over-year.

Meanwhile, insider trading activity has been notable. President Stephen Hoge sold 15,000 shares on June 17th, while CFO James M. Mock sold 1,321 shares on August 28th. Over the last quarter, insiders have sold a total of 108,158 shares, representing 15.70% of the company’s stock.

Institutional investors remain significantly invested in Moderna, with 75.33% of the stock owned by them. Notable investors include Sanctuary Advisors LLC, Teachers Retirement System of The State of Kentucky, Ariadne Wealth Management LP, Granite Bay Wealth Management LLC, and Truist Financial Corp.

Despite the recent mixed signals, Moderna continues to develop and commercialize messenger RNA therapeutics and vaccines for various diseases, including infectious diseases, cancer, and rare diseases.

**Disclaimer:** This news article is based on information provided in the original text and does not constitute financial advice. It is recommended to consult with a financial professional before making investment decisions.

Read More